- Home
- SVV vs XNCR Comparison
SVV vs XNCR Comparison
Compare SVV & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVV | XNCR |
|---|---|---|
| Founded | 1954 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SVV | XNCR |
|---|---|---|
| Price | $10.81 | $22.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $13.67 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $1,678,954,000.00 | $125,576,000.00 |
| Revenue This Year | $6.91 | N/A |
| Revenue Next Year | $7.80 | $4.80 |
| P/E Ratio | $107.10 | ★ N/A |
| Revenue Growth | 9.19 | ★ 13.65 |
| 52 Week Low | $6.91 | $7.13 |
| 52 Week High | $13.89 | $23.34 |
Technical Indicators
Market Signals| Indicator | SVV | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.21 | 73.11 |
| Support Level | $9.14 | $11.05 |
| Resistance Level | $11.38 | N/A |
| Average True Range (ATR) | 0.63 | 1.30 |
| MACD | 0.06 | 0.14 |
| Stochastic Oscillator | 49.18 | 91.74 |
Price Performance
Historical ComparisonAbout SVV Savers Value Village Inc.
Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second-hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, and sells these items in its stores.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.